Stocks · News reference
Ainos Notes Review Of Its One-Year, AI-Analyzed Breath Pattern Study Focusing On Chronic Obstructive Pulmonary Disease
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Ainos Rolls Out AI Nose Platform
Ainos, Inc. (NASDAQ:AIMD, AIMDW)) ("Ainos" or the "Company"), a pioneer in AI-powered Chemical Intelligence, today announced the next generation of its AI Nose platform, featuring comprehensive upgrades
Ainos’ AI Nose Platform Surpasses 878M Real-World Smell And Chemical Data Points, Primarily Generated From Semiconductor Manufacturing And Real-World Operating Environments
Dataset expands by approximately 265 million data points since July 21 as continued AI Nose system deployment across semiconductor manufacturing environments accelerates Ainos' Real-World Data Flywheel and Chemical
Ainos Q2 EPS $(0.62) Up From $(0.99) YoY, Sales $152.000K Up From $4.663K YoY
Ainos (NASDAQ:AIMD) reported quarterly losses of $(0.62) per share. This is a 37.37 percent increase over losses of $(0.99) per share from the same period last year. The company reported $152.000 thousand in sales this
8-K filing — Ainos, Inc. (AIMDW)
Filed: 2026-08-03 AccNo: 0001493152-26-035859 Size: 329 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits